Riskpilot← Back to searchSign inGet full accessBIO VITOS NORGE AS
ASActiveOrg 923663304Economic activity was not specified by tax authority · NACE 0000Est. 20190 employees
Revenue 2023
NOK 201K
EBITDA margin
72.5%
+408% vs 2022
Equity ratio
17.2%
Financial strength
Net profit 2023
NOK 178K
+476% vs 2022
| Revenue | NOK 201K | — |
| EBITDA | NOK 146K | +408% |
| Net profit | NOK 178K | +476% |
| Total assets | NOK 6,3M | +191% |
| Equity | NOK 1,1M | +20% |
| Employees | 0 | — |
Legal name
BIO VITOS NORGE AS
Org number
923663304
Legal form
Aksjeselskap
NACE code
0000 · Economic activity was not specified by tax authority
Founded
22. oktober 2019
Share capital
NOK 1 528 624
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Aktiv og varige investeringer i aksjer, eiendom og andre verdipapirer samt aktiv forvaltning av egne midler og investeringer. Fungere som rådgiver og konsulent for andre selskaper som trenger kompetanse innen de fagområder som norvolt trade & finance as besitter.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 201 |
| Staff expenses | −2 | −0 | −0 | −0 | −0 |
| EBITDA | −3 | −85 | −27 | −47 | 146 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −3 | −85 | −27 | −47 | 146 |
| Net financials | 0 | −678 | 109 | 0 | 32 |
| Profit before tax | −3 | −763 | 82 | −47 | 178 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −3 | −763 | 82 | −47 | 178 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 27 | 1 964 | 2 002 | 2 155 | 6 264 |
| Equity | 27 | 763 | 845 | 897 | 1 075 |
| Long-term debt | 0 | 0 | 0 | 0 | 5 139 |
| Short-term debt | 0 | 1 201 | 1 158 | 1 258 | 51 |
| Total debt | 0 | 1 201 | 1 158 | 1 258 | 5 189 |
EBITDA margin
72.5%
This company
15.8%
Market median
+359% vs market
20192023
Equity ratio
17.2%
This company
38.2%
Market median
-55% vs market
20192023
Return on equity
16.6%
This company
18.4%
Market median
+10% vs market
20192023
Net profit margin
88.6%
This company
8.1%
Market median
+994% vs market
20192023
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20192023
Debt / equity
4.83×
This company
0.62×
Market median
-679% vs market
20192023
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-09-19 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MS Chief Executive Officer | Chief Executive Officer | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Bio Vitos Medical Limited | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BIO VITOS NORGE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Morten Stokke Skjønberg | Chief Executive Officer | 0 companies |
| Harald Ole Anton Strokkenes | Chairman | 0 companies |